Xiaochen Shu

Xiaochen Shu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
JYJiazhen Yao
Jiazhen Yao
XCXiaohong Chen
Xiaohong Chen
FMFang Meng
Fang Meng
HCHanzhong Cao
Hanzhong Cao
XSXiaochen Shu
Xiaochen Shu

30 June 2023 in Clinical Nutrition
Verified
Journal Article
Closed access
HZHaifeng Zhang
Haifeng Zhang
YYYinshuang Yao
Yinshuang Yao
XZXiaoyan Zhong
Xiaoyan Zhong
FMFang Meng
Fang Meng
KHKari Hemminki
Kari Hemminki
XSXiaochen Shu
Xiaochen Shu

14 May 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
JQJunlan Qiu
Junlan Qiu
HZHaifeng Zhang
Haifeng Zhang
DXDongkui Xu
Dongkui Xu
LLLin Li
Lin Li
LXLingkai Xu
Lingkai Xu
XSXiaochen Shu
Xiaochen Shu
Background. Although radical cystectomy (RC) is the clinical practice guideline-recommended treatment of muscle-invasive bladder cancer (MIBC), bladder-sparing trimodality therapy (TMT) has emerged as a valid treatment option. Findings comparing the survival outcomes for MIBC patients who underwent RC and TMT are inconclusive. Objective. We designed a large hospital-based multicohort study to compare the effectiveness of TMT with RC. Methods. Information on deaths was jointly retrieved from EMR (electronic medical record), cause of death registry, and chronic disease surveillance as well as study-specific questionnaire. To avoid the systematical difference between patients who received two modalities, RC-MIBC cohort was propensity score-matched to TMT-MIBC cohort, and the Cox proportional hazard regression was used to calculate the overall survival (OS) and disease-specific survival (DSS). Results. There were 891 MIBC patients treated with RC and another 891 MIBC patients who underwent with TMT in the propensity score matching. Comparable effectiveness between two modalities was observed for DSS (HR, 1.20; 95 confidence interval (CI), 0.94 to 1.49) and OS (HR, 1.17; 95 CI, 0.91 to 1.43) according to multiple adjustment after a median follow-up of approximately 9.3 years. However, a relatively higher mortality rate around 5 years after TMT treatment was found compared to RC (HR, 1.26; 95 CI, 1.01 to 1.53). The respective 5-year OS rates were 69 and 73 for TMT cohort and RC cohort, respectively. Conclusions. Our findings supported that MIBC patients with TMT yielded survival outcomes comparable to MIBC patients who underwent RC overall. Treatment options should be suggested considering patients age and willingness.

29 November 2022 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
XCXiaohong Chen
Xiaohong Chen
JYJiazhen Yao
Jiazhen Yao
YXYirong Xin
Yirong Xin
GMGenshan Ma
Genshan Ma
YYYan Yu
Yan Yu
HCHanzhong Cao
Hanzhong Cao
Introduction Postoperative cancer pain imposes severe physical and psychological problems. We aimed to investigate the pain experiences of patients with cancer after surgery, analyze the impact of infusion volume by patient-controlled analgesia (PCA), and explore the variations between day 1 and day 2. Methods Data were retrospectively extracted from a large health data platform. Descriptive statistics were presented for the demographic and clinical profiles of patients. Multiple logistic regression analyses were performed to evaluate associations between intensity of pain and PCA use after adjustment for risk factors. Results Among 11,383 patients with cancer, the incidence of pain (moderate to severe pain) was 93.3% (18.3%) at the first 24 h after operation, while the respect values decreased to 91.1% and 9.5% at the second 24 h. Further, female patients consistently experienced higher risk of pain over the whole 48 h postoperatively. Surgical sites were related to pain risk, with the highest risk among the respiratory system (OR 2.077, 95% CI 1.392–3.100). High doses of continuous volume (OR 2.453, 95% CI 1.742–3.456) and total volume (OR 2.830, 95% CI 2.037–3.934) of infusions were related to 1–3-fold elevated pain risk. Additionally, the observed associations were mostly repeated and could be up to over 10 times when pain was evaluated with number of PCA pump compressions instead of Numerical Rating Scale (NRS). Conclusions High risk of postoperative cancer pain, particularly among the high PCA dose group, could possibly indicate inadequate pain control, and presence of modifiable risk factors warrants more aggressive pain management strategies perioperatively.

22 April 2019 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
YFYueyi Feng
Yueyi Feng
YJYiqing Jiang
Yiqing Jiang
TWTao Wen
Tao Wen
FMFang Meng
Fang Meng
XSXiaochen Shu
Xiaochen Shu

5 February 2025 in International Journal of Food Sciences and Nutrition
Verified
Journal Article
Closed access
JYJiazhen Yao
Jiazhen Yao
XCXiaohong Chen
Xiaohong Chen
YXYirong Xin
Yirong Xin
FMFang Meng
Fang Meng
XZXiaoyan Zhong
Xiaoyan Zhong
XSXiaochen Shu
Xiaochen Shu
Our study examined the relationship between diet quality and the prevalence of metabolic syndrome (MetS) among 1779 U.S. cancer survivors using data from the National Health and Nutrition Examination Survey (NHANES, 2005-2016). Diet quality was assessed using the Healthy Eating Index 2015 (HEI-2015). Higher HEI-2015 scores were linked to significantly lower MetS prevalence (OR: 0.51, 95% CI: 0.32-0.80). Specifically, a higher intake of seafood and plant proteins, and fatty acids, coupled with a reduced intake of added sugars, was associated with decreased odds of MetS prevalence (OR: 0.93; 95% CI, 0.86-0.99) in cancer survivors. Additionally, a better diet quality was linked to lower prevalence of high waist circumference, elevated triglycerides, reduced high-density lipoprotein (HDL) cholesterol and high fasting glucose levels (OR, 0.44; 95% CI, 0.27-0.72). These results suggest that adopting healthy dietary habits may prevent MetS in cancer survivors.